|
1
|
Badgwell D and Bast RC Jr: Early detection
of ovarian cancer. Dis Markers. 23:397–410. 2007. View Article : Google Scholar
|
|
2
|
Bast RC Jr: Early detection of ovarian
cancer: new technologies in pursuit of a disease that is neither
common nor rare. Trans Am Clin Climatol Assoc. 115:233–248.
2004.PubMed/NCBI
|
|
3
|
Morice P, Brehier-Ollive D, Rey A, et al:
Results of interval debulking surgery in advanced stage ovarian
cancer: an exposed-non-exposed study. Ann Oncol. 14:74–77. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Integrated genomic analyses of ovarian
carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
5
|
Donach M, Yu Y, Artioli G, et al: Combined
use of biomarkers for detection of ovarian cancer in high-risk
women. Tumour Biol. 31:209–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hensley ML: A step forward for two-step
screening for ovarian cancer. J Clin Oncol. 28:2128–2130. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liede A, Karlan BY, Baldwin RL, Platt LD,
Kuperstein G and Narod SA: Cancer incidence in a population of
Jewish women at risk of ovarian cancer. J Clin Oncol. 20:1570–1577.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tcherkassova J, Abramovich C, Moro R, Chen
C, Schmit R and Gerber A: Combination of CA125 and RECAF biomarkers
for early detection of ovarian cancer. Tumour Biol. 32:831–838.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Einhorn N, Sjovall K, Knapp RC, et al:
Prospective evaluation of serum CA 125 levels for early detection
of ovarian cancer. Obstet Gynecol. 80:14–18. 1992.PubMed/NCBI
|
|
10
|
Aslam N, Ong C, Woelfer B, Nicolaides K
and Jurkovic D: Serum CA125 at 11–14 weeks of gestation in women
with morphologically normal ovaries. BJOG. 107:689–690. 2000.
|
|
11
|
Menon U and Jacobs IJ: Recent developments
in ovarian cancer screening. Curr Opin Obstet Gynecol. 12:39–42.
2000. View Article : Google Scholar
|
|
12
|
Predanic M: Differentiating tubal abortion
from viable ectopic pregnancy with serum CA-125 and beta-human
chorionic gonadotropin determinations. Fertil Steril. 73:522–525.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Z, Bast RC Jr, Yu Y, et al: Three
biomarkers identified from serum proteomic analysis for the
detection of early stage ovarian cancer. Cancer Res. 64:5882–5890.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta D and Lis CG: Role of CA125 in
predicting ovarian cancer survival - a review of the
epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jacobs I and Bast RC Jr: The CA 125
tumour-associated antigen: a review of the literature. Hum Reprod.
4:1–12. 1989.PubMed/NCBI
|
|
16
|
Kim KA, Park CM, Lee JH, et al: Benign
ovarian tumors with solid and cystic components that mimic
malignancy. AJR Am J Roentgenol. 182:1259–1265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Helzlsouer KJ, Bush TL, Alberg AJ, Bass
KM, Zacur H and Comstock GW: Prospective study of serum CA-125
levels as markers of ovarian cancer. JAMA. 269:1123–1126. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bast RC Jr, Klug TL, St John E, et al: A
radioimmunoassay using a monoclonal antibody to monitor the course
of epithelial ovarian cancer. N Engl J Med. 309:883–887. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clarke CH, Yip C, Badgwell D, et al:
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and
connective tissue activating protein III enhance the sensitivity of
CA125 for detecting early stage epithelial ovarian cancer. Gynecol
Oncol. 122:548–553. 2011. View Article : Google Scholar
|
|
20
|
Woong-Shick A, Sung-Pil P, Su-Mi B, et al:
Identification of hemoglobin-alpha and -beta subunits as potential
serum biomarkers for the diagnosis and prognosis of ovarian cancer.
Cancer Sci. 96:197–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozak KR, Su F, Whitelegge JP, Faull K,
Reddy S and Farias-Eisner R: Characterization of serum biomarkers
for detection of early stage ovarian cancer. Proteomics.
5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beckman G, Eklund A, Frohlander N and
Stjernberg N: Haptoglobin groups and lung cancer. Hum Hered.
36:258–260. 1986. View Article : Google Scholar
|
|
23
|
Benkmann HG, Hanssen HP, Ovenbeck R and
Goedde HW: Distribution of alpha-1-antitrypsin and haptoglobin
phenotypes in bladder cancer patients. Hum Hered. 37:290–293. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abdullah M, Schultz H, Kahler D, et al:
Expression of the acute phase protein haptoglobin in human lung
cancer and tumor-free lung tissues. Pathol Res Pract. 205:639–647.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitchell RJ, Carzino R and Janardhana V:
Associations between the two serum proteins haptoglobin and
transferrin and leukaemia. Hum Hered. 38:144–150. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Awadallah SM and Atoum MF: Haptoglobin
polymorphism in breast cancer patients form Jordan. Clin Chim Acta.
341:17–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dunzendorfer U, Jung K and Ohlenschlager
G: Transferrin, C3 complement, haptoglobin, plasminogen and alpha
2-microglobulin in patients with urogenital tumors. Eur Urol.
6:232–236. 1980.PubMed/NCBI
|
|
28
|
Ye B, Cramer DW, Skates SJ, et al:
Haptoglobin-alpha subunit as potential serum biomarker in ovarian
cancer: identification and characterization using proteomic
profiling and mass spectrometry. Clin Cancer Res. 9:2904–2911.
2003.PubMed/NCBI
|
|
29
|
Zhao C, Annamalai L, Guo C, et al:
Circulating haptoglobin is an independent prognostic factor in the
sera of patients with epithelial ovarian cancer. Neoplasia. 9:1–7.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diamandis EP: Analysis of serum proteomic
patterns for early cancer diagnosis: drawing attention to potential
problems. J Natl Cancer Inst. 96:353–356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed N, Barker G, Oliva KT, et al:
Proteomic-based identification of haptoglobin-1 precursor as a
novel circulating biomarker of ovarian cancer. Br J Cancer.
91:129–140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hough CD, Sherman-Baust CA, Pizer ES, et
al: Large-scale serial analysis of gene expression reveals genes
differentially expressed in ovarian cancer. Cancer Res.
60:6281–6287. 2000.PubMed/NCBI
|
|
33
|
Chen YC, Pohl G, Wang TL, et al:
Apolipoprotein E is required for cell proliferation and survival in
ovarian cancer. Cancer Res. 65:331–337. 2005.PubMed/NCBI
|
|
34
|
Shih Ie M and Kurman RJ: Ovarian
tumorigenesis: a proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518.
2004.PubMed/NCBI
|
|
35
|
McIntosh MW, Drescher C, Karlan B, et al:
Combining CA 125 and SMR serum markers for diagnosis and early
detection of ovarian carcinoma. Gynecol Oncol. 95:9–15. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rosen DG, Wang L, Atkinson JN, et al:
Potential markers that complement expression of CA125 in epithelial
ovarian cancer. Gynecol Oncol. 99:267–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Anderson GL, McIntosh M, Wu L, et al:
Assessing lead time of selected ovarian cancer biomarkers: a nested
case-control study. J Natl Cancer Inst. 102:26–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palmer C, Duan X, Hawley S, et al:
Systematic evaluation of candidate blood markers for detecting
ovarian cancer. PLoS One. 3:e26332008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yurkovetsky Z, Skates S, Lomakin A, et al:
Development of a multimarker assay for early detection of ovarian
cancer. J Clin Oncol. 28:2159–2166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang B, Barekati Z, Kohler C, et al:
Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin
Lab Sci. 40:218–225. 2010.PubMed/NCBI
|
|
41
|
West-Norager M, Kelstrup CD, Schou C,
Hogdall EV, Hogdall CK and Heegaard NH: Unravelling in vitro
variables of major importance for the outcome of mass
spectrometry-based serum proteomics. J Chromatogr B Analyt Technol
Biomed Life Sci. 847:30–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu MY, Xydakis AM, Hoogeveen RC, et al:
Multiplexed analysis of biomarkers related to obesity and the
metabolic syndrome in human plasma, using the Luminex-100 system.
Clin Chem. 51:1102–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
